secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autonomix Medical, Inc. (AMIX)
CIK:        0001617867
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001437749-24-020591
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autonomix reports positive preliminary PoC trial results in pancreatic cancer pain patients; 60% responders
--------------------------------------------------------------------------------

- 60% of lead-in patients responded with mean 6.33 VAS pain reduction (8.0 to 1.67) at 7 days post-procedure.
- No procedural complications or significant adverse events in the first five patients.
- Responders reported 78% improvement in quality of health and 45% improvement in quality of life at 7 days.
- Femoral access patients responded; brachial access did not; trial enrollment on track for year-end 2024.
- Pain relief as quick as 1 day post-procedure; two patients succumbed to disease (expected, unrelated).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924020591/0001437749-24-020591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617867/000143774924020591/amix20240617_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-020591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer